This product is freely soluble in ethanol. No recommended dosage for cells is available.
1642802
USP
Tacrolimus
United States Pharmacopeia (USP) Reference Standard
Sinonimo/i:
FK-506 monohydrate, Tacrolimus
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Scegli un formato
100 MG
1.580,00 €
1.580,00 €
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Scegli un formato
Cambia visualizzazione
100 MG
1.580,00 €
About This Item
Formula empirica (notazione di Hill):
C44H69NO12 · H2O
Numero CAS:
Peso molecolare:
822.03
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24
1.580,00 €
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Prodotti consigliati
Grado
pharmaceutical primary standard
Famiglia di API
tacrolimus
Produttore/marchio commerciale
USP
applicazioni
pharmaceutical (small molecule)
Formato
neat
Stringa SMILE
O.CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@H]([C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)OC)[C@H](C[C@H]4C)OC
InChI
1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1
NWJQLQGQZSIBAF-MLAUYUEBSA-N
Informazioni sul gene
human ... FKBP1A(2280)
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Descrizione generale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Applicazioni
Tacrolimus USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Tacrolimus Capsules
- Tacrolimus Compounded Oral Suspension
Azioni biochim/fisiol
FK-506 is a potent immunosuppressant, neuroprotective and neuroregenerative, and in vitro T cell proliferation blocker. FK-506 disrupts calcineurin-mediated signal transduction in T lymphocytes and interacts with its FK-506-binding protein-12 (FKBP12).
FK-506 is a potent immunosuppressant; neuroprotective and neuroregenerative; in vitro T cell proliferation blocker.
Risultati analitici
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Altre note
Sales restrictions may apply.
Prodotti correlati
N° Catalogo
Descrizione
Determinazione del prezzo
Avvertenze
Danger
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Acute Tox. 3 Oral
Codice della classe di stoccaggio
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.
Se ti serve aiuto, non esitare a contattarci Servizio Clienti
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Tacrolimus
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 41(2), 4193-4193 (2021)
Tacrolimus Compounded Oral Suspension
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 41(1), 4202-4202 (2016)
Rania Rabie et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(1), 36-48 (2012-07-24)
Cyclosporine A (CSA), but not tacrolimus (TAC), inhibits hepatitis C virus (HCV) replication in vitro. Clinical reports on the efficacy of interferon-α (IFNα)-based antiviral therapy (AVT) for recurrent HCV after liver transplantation (LT) with CSA and TAC are conflicting. Our
Miwa Uesugi et al.
Pharmacogenetics and genomics, 24(7), 356-366 (2014-06-10)
We investigated whether the cytochrome P450 3A5*3 (CYP3A5*3) genotype affects tacrolimus pharmacokinetics and the risk of acute cellular rejection in living-donor liver transplant patients in Japan. Between July 2004 and June 2011, we enrolled 410 living-donor liver transplant patients receiving
Violette M G J Gijsen et al.
Pediatric transplantation, 17(3), 205-215 (2013-03-02)
Renal dysfunction after non-renal transplantation in adult tacrolimus-treated transplant patients is well documented. Little is known about its prevalence in children. Age-related changes in both disposition and effect of tacrolimus as well as renal function may preclude extrapolation of adult
-
How do I reconstitute this product (100mg), and what is the recommended dosage to treat 1x10^6 cells (human PBMC) with this product?
1 risposta-
Utile?
-
Filtri attivi
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.
